DHEA

Dehydroepiandrosterone (DHEA) is a steroid hormone primarily produced in the adrenal cortex and is the most abundant circulating steroid in primates. Researchers primarily study DHEA for its potential roles in aging, neuroprotection, and its effects on various organ systems. Key findings indicate that DHEA levels decline with age and are associated with several pathophysiological conditions, including adrenal insufficiency and systemic diseases, while its neurosteroidal properties suggest possible benefits in cognitive function and mood regulation. Clinical evidence indicates that DHEA may be beneficial in specific populations, such as individuals with adrenal insufficiency, but randomized controlled trials in healthy elderly subjects have not demonstrated significant advantages. Current research continues to explore the pharmacological effects and therapeutic applications of DHEA, particularly in relation to central nervous system disorders and its role in bone health among patients on glucocorticoid therapy.

Dehydroepiandrosterone (DHEA), also known as Prasterone or Intrarosa, is an endogenous steroid hormone primarily synthesized in the adrenal cortex. It is the most abundant steroid hormone in primates and belongs to the chemical class of sex hormones. DHEA levels exhibit a characteristic pattern of growth and decline throughout life, with peak production occurring in early adulthood and a gradual decrease with age. This hormone is also available in synthetic form for therapeutic uses. Researchers have extensively studied DHEA for its potential roles in various physiological processes and its implications in aging and disease. DHEA is involved in the conversion to sex steroids and exhibits neurosteroidal properties, influencing the central nervous system. It has been investigated for its potential neuroprotective, pro-cognitive, anxiolytic, and antidepressant effects. Additionally, DHEA has been studied for its role in conditions such as adrenal insufficiency, depression, and systemic lupus erythematosus (SLE), particularly in the context of bone mineral density preservation. Mechanistically, DHEA acts through conversion to active sex steroids and may interact with specific membrane receptors in various tissues, including endothelial cells, the heart, kidney, liver, and brain. Despite the absence of a specific intranuclear receptor, its metabolites exert wide-ranging effects. Pharmacokinetically, DHEA and its sulfate ester, DHEAS, circulate in the blood, predominantly bound to albumin. DHEA has a rapid metabolic clearance rate, while DHEAS is cleared more slowly. Both compounds can interconvert and are metabolized to androstenedione, testosterone, and estrogens in peripheral tissues. Clinically, DHEA is used in treating adrenal insufficiency and has been explored for its effects on bone density in SLE patients. While the FDA has granted orphan drug status for certain uses, it has not approved DHEA for anti-aging purposes due to insufficient evidence of benefit in healthy elderly individuals. DHEA is available as a dietary supplement in some regions, leading to potential misuse.

DHEA acts primarily by conversion to active sex steroids, such as testosterone and estrogens, in peripheral tissues. It may also exert direct effects via specific membrane receptors found in endothelial cells and other tissues, influencing various biological pathways and potentially contributing to neurosteroidal effects.

DHEA primarily exerts its effects through conversion to sex steroids, which then activate androgen and estrogen receptors, influencing androgen receptor signaling and estrogen receptor signaling pathways. Additionally, DHEA has been shown to interact with specific membrane receptors in various tissues, including the central nervous system, which may involve neurosteroid signaling pathways, although a specific intranuclear receptor for DHEA has not yet been identified. The exact mechanisms of action remain partially understood, particularly regarding its neuroprotective and cognitive effects.

Current evidence is limited regarding the long-term effects and safety of DHEA supplementation in healthy elderly populations, as existing randomized controlled trials have not demonstrated significant benefits and raised concerns about potential adverse effects. Further research is needed to explore the mechanisms of action of DHEA and its metabolites in various organ systems, particularly in the central nervous system, as well as to clarify the role of DHEA in specific populations, such as those with chronic diseases or hormonal imbalances. Additionally, larger studies are required to investigate the pharmacokinetics and pharmacodynamics of different DHEA formulations, including prasterone, to better understand their therapeutic potential and safety profiles in diverse patient groups.